Quick Takeaways
- PERCEPTIVE ADVISORS LLC filed SCHEDULE 13G for CytomX Therapeutics, Inc. Common Stock, $0.00001 par value per share (CTMX).
- Disclosed ownership: 5.9%.
- Date of event: 14 Aug 2025.
PERCEPTIVE ADVISORS LLC - 14 Aug 2025 SCHEDULE 13G Report for CytomX Therapeutics, Inc. Common Stock, $0.00001 par value per share (CTMX)
- Filing Manager
- PERCEPTIVE ADVISORS LLC
- Reporting Manager
- Perceptive Advisors LLC
- Symbol
- CTMX
- Shares outstanding
- 164,070,932 shares
- Disclosed Ownership
- 9,680,185 shares
- Ownership
- 5.9%
- Form type
- SCHEDULE 13G
- Filing time
- 21 Aug 2025, 16:00:03 UTC
- Date of event
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"PERCEPTIVE ADVISORS LLC disclosed 5.9% ownership in CytomX Therapeutics, Inc. Common Stock, $0.00001 par value per share (CTMX) on 14 Aug 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 21 Aug 2025, 16:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | 5.9% | 9,680,185 | 0 | 9,680,185 | /s/ Joseph Edelman | Joseph Edelman, Managing Member | |
| Joseph Edelman | 5.9% | 9,680,185 | 0 | 9,680,185 | /s/ Joseph Edelman | Joseph Edelman | |
| Perceptive Life Sciences Master Fund, Ltd. | 5.9% | 9,680,185 | 0 | 9,680,185 | /s/ Joseph Edelman | Joseph Edelman, Managing Member |